European Journal of Cancer
Volume 41, Issue 18 , Pages 2868-2872 , December 2005

Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study

  • Wim G. Goettsch

      Affiliations

    • PHARMO Institute, Utrecht, The Netherlands
    • ,
  • Steffan D. Bos

      Affiliations

    • PHARMO Institute, Utrecht, The Netherlands
    • Department of Pathology, Leiden University Medical Center, Building 1, L1Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands
    • ,
  • Nancy Breekveldt-Postma

      Affiliations

    • PHARMO Institute, Utrecht, The Netherlands
    • ,
  • Mariel Casparie

      Affiliations

    • Foundation PALGA, Utrecht, The Netherlands
    • ,
  • Ron M.C. Herings

      Affiliations

    • PHARMO Institute, Utrecht, The Netherlands
    • Department of Pharmacoepidemiology and Therapy, UIPS, Utrecht University, Utrecht, The Netherlands
    • ,
  • Pancras C.W. Hogendoorn

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Building 1, L1Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 71 5269111; fax: +31 71 5142588.

Received 4 August 2005 ,Revised 13 September 2005 ,Accepted 13 September 2005.

References 

  1. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15(4):1293–1301
  2. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438(1):1–12
  3. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(Suppl. 5):S37–S38
  4. D’Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12(1):44–56
  5. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–1134
  6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med. 2002;347(7):472–480
  7. Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33(5):466–477
  8. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(Suppl. 5):S39–S51
  9. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer. 2005;103(4):821–829
  10. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54(2):96–102
  11. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–465
  12. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11(8):728–734
  13. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–1269
  14. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29(5):498–504
  15. Blay J-Y, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16(4):566–578
  16. Trent J. A prospective, randomized, phase II study of preoperative plus postoperative imatinib mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent or metastatic resectable kit-expressing, gastrointestinal tumor (GIST). Available from: http://utmext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/index/ID03-0023.; 2004.

PII: S0959-8049(05)00797-5

doi: 10.1016/j.ejca.2005.09.009

European Journal of Cancer
Volume 41, Issue 18 , Pages 2868-2872 , December 2005

Article Tools

* Image Usage & Resolution